Merrimack Pharma (MACK) is a cancer biotech with a diverse early-late stage clinical development pipeline that is summarized below.
CLINICAL TRIAL CATALYSTS (status updated in 7/12 SEC 424B5 prospectus filing related to recent offering):
1.) MM-398 (novel encapsulated liposomal formulation of approved anti-cancer drug irinotecan) is currently being evaluated in a Phase III (NAPOLI-1) clinical trial with expected completion of enrollment during Q3 2013 and top-line results expected during Q4 2013 to Q1 2014.
MM-398 is being evaluated for the treatment of metastatic pancreatic cancer that has progressed on gemcitabine treatment (i.e. a second-line treatment indication). ClinicalTrials.gov ID NCT01494506 is the identifier for the study and MM-398 has US and EU Orphan Drug status and...